Pfizer (NYSE:PFE) Stock Jumps 1.6% - Time to Buy?

Key Points

• Pfizer shares rose 1.6% to about $29.91 after the company reported positive Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, supporting plans for global regulatory submissions.
• Analysts remain cautious, with a consensus “Hold” rating and a $28.72 price target, as investors weigh declining COVID-related sales, patent expirations and the ability of newer products—including obesity treatments—to drive growth.
• Pfizer declared a quarterly dividend of $0.43 per share, equivalent to a 5.8% annualized yield, although its payout ratio is elevated at 226.32%.

Pfizer Inc. (NYSE:PFE - Get Free Report) shares traded up 1.6% during trading on Thursday. The company traded as high as $30.18 and last traded at $29.9130. Approximately 28,752,573 shares were traded during trading, a decline of 27% from the average daily volume of 39,612,625 shares. The stock had previously closed at $29.45.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its ELREXFIO treatment met the primary endpoint in the Phase 3 MagnetisMM-32 trial for relapsed or refractory multiple myeloma, delivering a statistically significant and clinically meaningful progression-free-survival benefit versus standard regimens. The company plans global regulatory submissions, strengthening confidence in its oncology pipeline. Pfizer Scores Phase 3 Cancer Win
• Positive Sentiment: Scotiabank initiated coverage of Pfizer with a Buy rating, providing a favorable analyst signal ahead of the company’s quarterly results. Pfizer Gets a Buy from Scotiabank
• Positive Sentiment: Pfizer agreed to work with Edison Scientific to accelerate research and development. Although financial terms were not disclosed, the collaboration could support the company’s productivity and pipeline ambitions. Edison Scientific Announces Agreement with Pfizer
• Neutral Sentiment: Analysts are focused on Pfizer’s third-quarter results, scheduled for November 3. The key issues will be whether non-COVID products and progress in obesity treatments can offset continued erosion in pandemic-related revenue. Obesity Pipeline vs. COVID Drag
• Neutral Sentiment: A market report projects the global HER2-targeted therapies market will expand at roughly an 8% annual rate, highlighting growth opportunities for Pfizer and other companies developing antibody-drug conjugates and precision-oncology therapies. The report does not announce a new Pfizer deal or product. Global HER2 Targeted Therapies Market Report
• Negative Sentiment: Investor concerns remain centered on shrinking COVID-related sales, upcoming patent expirations and uncertainty over whether newer medicines—including obesity candidates—can replace lost pandemic revenue. These issues could limit upside if Pfizer’s earnings outlook disappoints. Pfizer Stock Ahead of Q3 Earnings

Analyst Upgrades and Downgrades

PFE has been the topic of several analyst reports. Weiss Ratings raised Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, August 31st. BMO Capital Markets decreased their target price on Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday, July 13th. JPMorgan Chase & Co. upped their price target on Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research note on Friday, October 9th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, October 13th. Finally, Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Saturday, October 10th. Five analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $28.72.

Pfizer Trading Up 1.6%

The business has a 50 day simple moving average of $28.46 and a 200-day simple moving average of $26.74. The stock has a market capitalization of $170.49 billion, a price-to-earnings ratio of 39.36, a PEG ratio of 2.04 and a beta of 0.32. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the previous year, the business posted $0.78 EPS. Pfizer's revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.8%. The ex-dividend date is Friday, November 6th. Pfizer's dividend payout ratio (DPR) is presently 226.32%.

Hedge Funds Weigh In On Pfizer

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. TOWER TRUST & INVESTMENT Co increased its position in shares of Pfizer by 1.9% during the 3rd quarter. TOWER TRUST & INVESTMENT Co now owns 19,322 shares of the biopharmaceutical company's stock valued at $551,000 after purchasing an additional 357 shares during the last quarter. Angeles Wealth Management LLC lifted its position in Pfizer by 2.2% in the 2nd quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company's stock worth $410,000 after buying an additional 358 shares during the last quarter. Manchester Financial Inc. lifted its position in Pfizer by 2.9% in the 2nd quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company's stock worth $317,000 after buying an additional 365 shares during the last quarter. Delta Financial Advisors LLC lifted its position in Pfizer by 1.6% in the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company's stock worth $709,000 after buying an additional 398 shares during the last quarter. Finally, Mount Vernon Associates Inc. MD boosted its stake in Pfizer by 1.0% in the first quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company's stock worth $1,177,000 after buying an additional 400 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company's portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.